Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset
Hoth Therapeutics (NASDAQ: HOTH) announced its Board of Directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset. The company cites Bitcoin's growing investor acceptance, recent ETF approvals, and increased institutional investor activity as key factors in this decision. CEO Robb Knie emphasized Bitcoin's potential as an inflation-resistant store of value and its emergence as a major asset class.
Hoth Therapeutics (NASDAQ: HOTH) ha annunciato che il suo Consiglio di Amministrazione ha approvato l'acquisto di fino a 1 milione di dollari in Bitcoin come attivo di riserva di tesoreria. L'azienda cita l'accettazione crescente del Bitcoin da parte degli investitori, le recenti approvazioni di ETF e l'aumento dell'attività degli investitori istituzionali come fattori chiave di questa decisione. Il CEO Robb Knie ha sottolineato il potenziale del Bitcoin come riserva di valore resistente all'inflazione e la sua affermazione come una classe di attivo importante.
Hoth Therapeutics (NASDAQ: HOTH) anunció que su Junta Directiva ha aprobado la compra de hasta 1 millón de dólares en Bitcoin como un activo de reserva de tesorería. La compañía cita la creciente aceptación de Bitcoin por parte de los inversores, las recientes aprobaciones de ETF, y un aumento en la actividad de los inversores institucionales como factores clave en esta decisión. El CEO Robb Knie enfatizó el potencial de Bitcoin como un almacén de valor resistente a la inflación y su emergente posición como una clase de activo importante.
Hoth Therapeutics (NASDAQ: HOTH)는 이사회가 100만 달러의 비트코인 구매를 재무 자산으로 승인했다고 발표했습니다. 이 회사는 비트코인의 투자자 수용 증가, 최근 ETF 승인 및 기관 투자자의 활동 증가를 이 결정의 주요 요소로 꼽았습니다. CEO 로브 니에(Robb Knie)는 비트코인의 인플레이션 저항 가치 저장 수단으로서의 잠재력과 주요 자산 클래스로서의 출현을 강조했습니다.
Hoth Therapeutics (NASDAQ: HOTH) a annoncé que son Conseil d'Administration avait approuvé l'achat de jusqu'à 1 million de dollars en Bitcoin comme actif de réserve de trésorerie. L'entreprise cite l'acceptation croissante du Bitcoin par les investisseurs, les récentes approbations d'ETF et l'augmentation de l'activité des investisseurs institutionnels comme des facteurs clés de cette décision. Le PDG Robb Knie a souligné le potentiel du Bitcoin en tant qu'outil de conservation de valeur résistant à l'inflation et son émergence en tant que classe d'actifs majeure.
Hoth Therapeutics (NASDAQ: HOTH) hat bekannt gegeben, dass der Vorstand den Kauf von bis zu 1 Million Dollar in Bitcoin als Reservevermögen genehmigt hat. Das Unternehmen verweist auf die wachsende Akzeptanz von Bitcoin bei Investoren, die kürzlichen ETF-Zulassungen und die steigende Aktivität institutioneller Investoren als Schlüssel Faktoren für diese Entscheidung. CEO Robb Knie betonte das Potenzial von Bitcoin als inflationssichere Wertaufbewahrung und seinen Aufstieg als bedeutende Anlageklasse.
- Board approval for diversification of treasury assets with Bitcoin investment up to $1 million
- Strategic move to potentially hedge against inflation through cryptocurrency exposure
- Exposure to cryptocurrency volatility risks
- Significant allocation of company resources to a highly speculative asset
- Potential impact on balance sheet stability due to Bitcoin price fluctuations
"As Bitcoin continues to grow, gaining investor attention and acceptance as a major and primary asset class, we believe that Bitcoin will serve as a strong treasury reserve asset," said Robb Knie, CEO of Hoth. "With recent approval of Bitcoin ETFs and increasing activity from institutional investors, it is a strong addition to our treasury strategy. We believe its inflation-resistant characteristics may make it a reliable asset as a functional store of value."
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of any health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; our cash needs and financing plans; and the long-term value of Bitcoin. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions, risks inherent with investing in Bitcoin, including Bitcoin's volatility and risk of implementing a new Bitcoin treasury strategy, and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-Kas amended or supplemented by Hoth's other filings made with the
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-board-of-directors-approves-bitcoin-as-treasury-reserve-asset-302311213.html
SOURCE Hoth Therapeutics, Inc.
FAQ
How much Bitcoin investment did Hoth Therapeutics (HOTH) board approve?
Why did Hoth Therapeutics (HOTH) decide to invest in Bitcoin?
When did Hoth Therapeutics (HOTH) announce its Bitcoin investment plan?
What is the maximum amount HOTH plans to invest in Bitcoin?
